CONCORDBIO: Revenue declined 12% in FY 2026, but strong growth and margin improvement are expected in FY 2027

About this update from Concord Biotech Ltd.

FY 2026 saw a 12% revenue decline due to geopolitical and supply chain disruptions, but profitability remained resilient with a 35% EBITDA margin. Management expects FY 2027 growth to exceed historical rates, supported by new facilities, regulatory approvals, and operating leverage.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Concord Biotech Ltd.